-
LIXT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Lixte Biotechnology (LIXT)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 108.75 mm |
Total shares | 135.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Warberg Asset Management | 53.18 k | $3.71 mm |
Ethos Financial | 42.11 k | $3.63 mm |
Clear Street | 23.15 k | $2.00 k |
Geode Capital Management | 10.12 k | $58.99 mm |
MS Morgan Stanley | 7.11 k | $41.78 mm |
UBS UBS | 101.00 | $594.00 k |
Tower Research Capital | 8.00 | $47.00 k |
Proequities | 0.00 | $0.00 |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep 24 | Regina Brown | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.3 | 6,269 | 8.15 k | 6,269 |
30 Sep 24 | Rene Bernards | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.3 | 5,304 | 6.90 k | 5,304 |
30 Sep 24 | Stephen J. Forman | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.3 | 3,858 | 5.02 k | 3,858 |
30 Sep 24 | Yun Yen | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.3 | 5,786 | 7.52 k | 5,786 |